We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

Cell Projects licenses Electroporation Technologies from Queen’s University, Canada

Read time: Less than a minute

Cell Projects has entered into a wide ranging commercial license and joint development agreement with Queen’s University, Kingston, Ontario, Canada, covering several new Electroporation platform technologies for Adherent and InSitu Cell Electroporation.

The technology allows DNA, peptides, siRNA and many other molecules to be gently transported into cultured, adherent cells while the cells are still attached to their growing surface. The data shows dramatic improvements of sensitivity and operation over existing methodologies.

Tom Hole MD at Cell Projects says “the InSitu technology will enable a greater understanding of specific cellular activities that to date have been difficult to analyze yet are known to be important in further understanding the mechanism of cancer, and other biological problems”.